Max Bayer – Page 13 – Endpoints News

about the author

Max Bayer

Pharma Reporter

mbayer@endpointsnews.com

author articles

Sanofi sues Sarepta, alleging that Duchenne treatment Elevidys infringes on AAV patents

11 months ago

Biosecure lawmakers tell trade groups that China studies are a new focus

11 months ago

China corruption crackdown hits Merck’s Gardasil sales, spooking investors

11 months ago

Keytruda tops $7B quarterly sales for the first time

11 months ago

NewAmsterdam succeeds in the first of three key pivotal studies, providing hope to a troubled cardio class

11 months ago

Among pharma CEOs, the IRA now and the IRA later get very different reactions

11 months ago

EU panel follows FDA’s lead on Wegovy, recommending use to prevent cardiac events

11 months ago

Sanofi shelves four assets, including mid-stage dwarfism candidate

11 months ago

BioMarin snags expanded Brineura label, now approved for all kids regardless of symptoms

11 months ago

US bankrolls a third of global Pandemic Fund. Can it get congressional support?

11 months ago

Novartis pays $150M upfront, including $25M in equity, for Dren Bio’s bispecifics

11 months ago

Updated: Merck, without sharing details, says RSV antibody successfully protected infants

11 months ago

Chinese biotech boasts competitive Phase 2b weight loss data for GLP-1 drug

11 months ago

Vermont attorney general sues two major PBMs for allegedly driving up costs

11 months ago

US inks $113M deal with Siga to bolster smallpox, mpox reserves

11 months ago

Roivant recently sold one spinout for billions. Is Priovant next?

11 months ago

Nadir Mahmood returns to Nkarta a year after leaving; BeiGene picks longtime Merck exec for CFO post

11 months ago

Novartis CEO: Trying to crack obesity market with another first-gen agent is 'not a prudent approach'

11 months ago

Cassava founder and CEO resigns as federal probes progress

11 months ago

Federal judge dismisses Hawaii’s lawsuit against top three PBMs

11 months ago

Roche details early obesity data from GLP-1/GIP agonist, plans for Phase 2 study this year

11 months ago

Facing a tepid Alzheimer’s market, Lilly looks to build ‘a sense of urgency’ to jumpstart sales of donanemab

11 months ago

Lilly says lupus drug dropped from pipeline failed to show efficacy

12 months ago

Indivior axes schizophrenia drug and shrinks revenue guidance

12 months ago

First page Previous page 10 11 121314 15 Next page Last page